Catalyst Event
Johnson & Johnson (JNJ) · Other
From Akros SCHK HK-Global Momentum Factor Index (ASHGMOM)
6/3/2026, 12:00:00 AM
Johnson & Johnson announced on June 3, 2026, that its monoclonal antibody, nipocalimab, met the primary endpoint in the Phase 2 JASMINE study for SLE; positive clinical data for a major pipeline candidate is estimated to have a 5-10% market impact, expected.
Korean Translation
2026년 6월 3일, Johnson & Johnson은 니포칼리맙의 2상 JASMINE 연구에서 1차 평가변수를 충족했다고 발표함. 주요 파이프라인의 긍정적인 임상 데이터는 5-10%의 시장 영향을 미칠 것으로 예상됨.
Related Recent Events
Sun Hung Kai Properties Ltd (16) · Earnings Release
Full year results for fiscal year 2026 scheduled.
9/3/2026, 12:00:00 AM
COSCO SHIPPING Energy Transportation Co. Ltd. (1138) · Other
Ex-dividend date for the 2025 final dividend of HKD 0.43007 per share on 2026-07-17; market analysts justify medium impact due to dividend payout; event scheduled.
7/17/2026, 12:00:00 AM
Sinotruk (Hong Kong) Ltd (3808) · Other
Ex-dividend date for the HK$0.88 per share final dividend for the year ended December 31, 2025, is scheduled for July 9, 2026; low importance as a routine technical adjustment is scheduled.
7/9/2026, 12:00:00 AM
The Bank of Nova Scotia (BNS) · Other
A quarterly dividend of C$1.14 per share, a 4% increase, is scheduled with an ex-dividend date of July 7, 2026; low importance is estimated based on the typical market reaction to dividend increases, scheduled.
7/7/2026, 12:00:00 AM
Iberdrola SA (IBE) · Other
The ex-dividend date for the complementary dividend payment of approximately €0.43 per share is scheduled for July 6, 2026, with an estimated 1% price impact, scheduled.
7/6/2026, 12:00:00 AM
Yangtze Optical Fibre And Cable Joint Stock Ltd Co (6869) · Other
Ex-dividend date of 2026-07-03 for a proposed final dividend of RMB 0.295 per share for the year ended Dec 31, 2025, with payment on 2026-08-21 following approval on 2026-06-30; the dividend is expected to have a price impact of at least 1% scheduled
7/3/2026, 12:00:00 AM